Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial.
Joseph G TimmonsNicola GreenlawJames G BoyleNish ChaturvediIan FordMartijn C G J BrouwersTherese TillinIrene HramiakAlun D HughesAlicia J JenkinsBarbara E K KleinRon KleinTeik C OoiPeter RossingCoen D A StehouwerNaveed SattarHelen Martina ColhounJohn R Petrienull nullPublished in: Diabetes, obesity & metabolism (2021)
This subgroup analysis of the REMOVAL trial provides additional support for a potentially wider role of adjunct metformin therapy in cardiovascular risk management in type 1 diabetes, particularly for individuals who have never smoked cigarettes.
Keyphrases
- phase iii
- type diabetes
- smoking cessation
- study protocol
- phase ii
- clinical trial
- open label
- cardiovascular disease
- randomized controlled trial
- optical coherence tomography
- replacement therapy
- insulin resistance
- glycemic control
- cardiovascular risk factors
- double blind
- stem cells
- metabolic syndrome
- bone marrow
- placebo controlled
- cell therapy